

# **Global Metastatic Bone Disease Market Size Study, By End-Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), By Origin of Metastasis (Breast, Lung, Thyroid, Kidney, Prostate, Others), By Treatment (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy), and Regional Forecasts 2022-2032**

<https://marketpublishers.com/r/GED74A0FDBC9EN.html>

Date: January 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: GED74A0FDBC9EN

## **Abstracts**

This substantial growth is attributed to the rising global incidence of cancer and advancements in therapeutic approaches that include radiopharmaceuticals, bisphosphonates, and other bone-targeting agents. These innovations have significantly enhanced the effectiveness of MBD treatments, improving patient quality of life by managing pain and reducing bone resorption. The development of minimally invasive surgical techniques and the adoption of advanced imaging technologies like MRI and PET scans have further revolutionized the management of metastatic bone disease, enabling precise diagnosis and personalized care.

The increasing emphasis on palliative care and the integration of multimodal treatment strategies, such as combining medications with radiation therapy and surgical interventions, have further supported market expansion. Key regions like North America and Asia-Pacific are witnessing robust growth, driven by advanced healthcare infrastructures and the rising prevalence of cancers in emerging economies.

The competitive landscape is characterized by significant investments in R&D and the introduction of innovative treatment modalities. Leading companies are focusing on developing targeted therapies to address the diverse needs of patients while ensuring quality-of-life improvements. Regional trends also reveal promising opportunities in

emerging markets, fueled by improved healthcare access and rising demand for palliative care solutions.

Major market players included in this report are:

1. Amgen, Inc.
2. Bayer AG
3. Boston Scientific Corporation
4. BTG PLC
5. Eli Lilly and Company
6. F. Hoffmann-La Roche AG
7. Fresenius Kabi
8. Medtronic
9. Merck & Co., Inc.
10. Novartis AG
11. Pfizer Inc.
12. Johnson & Johnson
13. Zimmer Biomet
14. Smith & Nephew
15. Stryker Corporation

The detailed segments and sub-segments of the market are explained below:

By End-Use:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

By Origin of Metastasis:

Breast

Lung

Thyroid

Kidney

Prostate

Others

By Treatment:

Medication

Radiation Therapy

Surgical Intervention

Tumor Ablation Therapy

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia-Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

1. The global metastatic bone disease market is projected to grow during 2024-2032.
2. Innovations in imaging technologies, such as MRI and PET scans, are driving early diagnosis and effective treatment strategies.
3. The U.S. leads the market with advanced healthcare infrastructure, while Asia-Pacific emerges as a high-growth region due to increasing cancer prevalence.
4. Multimodal treatment approaches, combining radiation therapy, medication, and surgical interventions, are gaining prominence.
5. Major players include Amgen, Bayer AG, Eli Lilly, and Boston Scientific, with a focus on developing targeted and personalized therapies.

## Contents

### **CHAPTER 1. GLOBAL METASTATIC BONE DISEASE MARKET EXECUTIVE SUMMARY**

- 1.1. Global Metastatic Bone Disease Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
  - 1.3.1. By End-Use
  - 1.3.2. By Origin of Metastasis
  - 1.3.3. By Treatment
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

### **CHAPTER 2. GLOBAL METASTATIC BONE DISEASE MARKET DEFINITION AND RESEARCH ASSUMPTIONS**

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
  - 2.3.1. Inclusion & Exclusion
  - 2.3.2. Limitations
  - 2.3.3. Supply Side Analysis
    - 2.3.3.1. Availability
    - 2.3.3.2. Infrastructure
    - 2.3.3.3. Regulatory Environment
    - 2.3.3.4. Market Competition
    - 2.3.3.5. Economic Viability (Consumer's Perspective)
  - 2.3.4. Demand Side Analysis
    - 2.3.4.1. Regulatory Frameworks
    - 2.3.4.2. Technological Advancements
    - 2.3.4.3. Environmental Considerations
    - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

### **CHAPTER 3. GLOBAL METASTATIC BONE DISEASE MARKET DYNAMICS**

*Global Metastatic Bone Disease Market Size Study, By End-Use (Hospitals, Specialty Clinics, Ambulatory Surgica...*

### 3.1. Market Drivers

- 3.1.1. Increasing Global Cancer Burden
- 3.1.2. Advancements in Imaging and Diagnostics
- 3.1.3. Rising Demand for Palliative Care

### 3.2. Market Challenges

- 3.2.1. High Treatment Costs
- 3.2.2. Limited Access to Advanced Healthcare in Developing Regions

### 3.3. Market Opportunities

- 3.3.1. Expansion of Multimodal Treatment Approaches
- 3.3.2. Investment in R&D for Targeted Therapies

## **CHAPTER 4. GLOBAL METASTATIC BONE DISEASE MARKET INDUSTRY ANALYSIS**

### 4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry

### 4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

### 4.3. Top Investment Opportunities

### 4.4. Top Winning Strategies

### 4.5. Disruptive Trends

### 4.6. Analyst Recommendations & Conclusion

## **CHAPTER 5. GLOBAL METASTATIC BONE DISEASE MARKET SIZE & FORECASTS BY END-USE (2022-2032)**

### 5.1. Hospitals

### 5.2. Specialty Clinics

### 5.3. Ambulatory Surgical Centers

## **CHAPTER 6. GLOBAL METASTATIC BONE DISEASE MARKET SIZE & FORECASTS BY ORIGIN OF METASTASIS (2022-2032)**

- 6.1. Breast
- 6.2. Lung
- 6.3. Thyroid
- 6.4. Kidney
- 6.5. Prostate
- 6.6. Others

## **CHAPTER 7. GLOBAL METASTATIC BONE DISEASE MARKET SIZE & FORECASTS BY TREATMENT (2022-2032)**

- 7.1. Medication
- 7.2. Radiation Therapy
- 7.3. Surgical Intervention
- 7.4. Tumor Ablation Therapy

## **CHAPTER 8. GLOBAL METASTATIC BONE DISEASE MARKET SIZE & FORECASTS BY REGION (2022-2032)**

- 8.1. North America
  - 8.1.1. U.S.
  - 8.1.2. Canada
- 8.2. Europe
  - 8.2.1. UK
  - 8.2.2. Germany
  - 8.2.3. France
  - 8.2.4. Spain
  - 8.2.5. Italy
  - 8.2.6. Rest of Europe
- 8.3. Asia-Pacific
  - 8.3.1. China
  - 8.3.2. India
  - 8.3.3. Japan
  - 8.3.4. Australia
  - 8.3.5. South Korea
  - 8.3.6. Rest of Asia-Pacific



#### 8.4. Latin America

##### 8.4.1. Brazil

##### 8.4.2. Mexico

##### 8.4.3. Rest of Latin America

#### 8.5. Middle East & Africa

##### 8.5.1. Saudi Arabia

##### 8.5.2. South Africa

##### 8.5.3. Rest of Middle East & Africa

### **CHAPTER 9. COMPETITIVE INTELLIGENCE**

#### 9.1. Key Company SWOT Analysis

##### 9.1.1. Amgen

##### 9.1.2. Bayer

##### 9.1.3. Boston Scientific

#### 9.2. Top Market Strategies

#### 9.3. Company Profiles

##### 9.3.1. Eli Lilly

##### 9.3.2. Merck

##### 9.3.3. Novartis

### **CHAPTER 10. RESEARCH PROCESS**

#### 10.1. Research Attributes

#### 10.2. Data Mining

#### 10.3. Analysis Techniques

#### 10.4. Data Validation

### **12. LIST OF TABLES**

#### **1. GLOBAL METASTATIC BONE DISEASE MARKET ESTIMATES & FORECASTS BY REGION (2022-2032)**

#### **2. GLOBAL METASTATIC BONE DISEASE MARKET ESTIMATES & FORECASTS BY TREATMENT TYPE (2022-2032)**

#### **3. U.S. METASTATIC BONE DISEASE MARKET ESTIMATES & FORECASTS (2022-2032)**

**4. ASIA-PACIFIC METASTATIC BONE DISEASE MARKET ESTIMATES & FORECASTS BY TREATMENT (2022-2032)****5. EUROPE METASTATIC BONE DISEASE MARKET ESTIMATES & FORECASTS BY END-USE (2022-2032)****6. MIDDLE EAST & AFRICA MARKET SEGMENTATION BY TREATMENT TYPE (2022-2032)****7. LATIN AMERICA METASTATIC BONE DISEASE MARKET SEGMENTATION BY TREATMENT (2022-2032)****8. COMPARISON OF TOP PLAYERS IN THE METASTATIC BONE DISEASE MARKET**

This list is not complete. The final report contains over 100 tables. The list may be updated in the final deliverable.

**12. LIST OF FIGURES****1. METASTATIC BONE DISEASE MARKET GROWTH BY REGION (2022-2032)****2. METASTATIC BONE DISEASE MARKET SEGMENTATION BY TREATMENT (2022-2032)****3. KEY PLAYERS' MARKET SHARE ANALYSIS (2024)****4. NORTH AMERICA METASTATIC BONE DISEASE MARKET GROWTH (2022-2032)****5. EUROPE MARKET TRENDS BY TREATMENT TYPE (2022-2032)****6. EMERGING ASIA-PACIFIC MARKETS FOR METASTATIC BONE DISEASE****7. TECHNOLOGICAL ADOPTION RATES IN MBD TREATMENTS (2022-2032)****8. COMPETITIVE LANDSCAPE OVERVIEW OF MAJOR PLAYERS**

This list is not complete. The final report contains over 50 figures. The list may be

updated in the final deliverable.

## I would like to order

Product name: Global Metastatic Bone Disease Market Size Study, By End-Use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), By Origin of Metastasis (Breast, Lung, Thyroid, Kidney, Prostate, Others), By Treatment (Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy), and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GED74A0FDBC9EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GED74A0FDBC9EN.html>